|
1
|
Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer.
|
J Clin Oncol
|
2005
|
5.10
|
|
2
|
KIF5B-RET fusions in lung adenocarcinoma.
|
Nat Med
|
2012
|
4.38
|
|
3
|
Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial.
|
Lancet Oncol
|
2009
|
3.69
|
|
4
|
Comprehensive histologic analysis of ALK-rearranged lung carcinomas.
|
Am J Surg Pathol
|
2011
|
2.21
|
|
5
|
EGFR mutations predict survival benefit from gefitinib in patients with advanced lung adenocarcinoma: a historical comparison of patients treated before and after gefitinib approval in Japan.
|
J Clin Oncol
|
2008
|
1.50
|
|
6
|
Randomized pharmacokinetic and pharmacodynamic study of docetaxel: dosing based on body-surface area compared with individualized dosing based on cytochrome P450 activity estimated using a urinary metabolite of exogenous cortisol.
|
J Clin Oncol
|
2005
|
1.50
|
|
7
|
Influence of previous chemotherapy on the efficacy of subsequent docetaxel therapy in advanced non-small cell lung cancer patients.
|
J Thorac Oncol
|
2008
|
1.47
|
|
8
|
Epidermal growth factor receptor mutation detection using high-resolution melting analysis predicts outcomes in patients with advanced non small cell lung cancer treated with gefitinib.
|
Clin Cancer Res
|
2007
|
1.34
|
|
9
|
Prospective study of the accuracy of EGFR mutational analysis by high-resolution melting analysis in small samples obtained from patients with non-small cell lung cancer.
|
Clin Cancer Res
|
2008
|
1.31
|
|
10
|
Risk factors for interstitial lung disease and predictive factors for tumor response in patients with advanced non-small cell lung cancer treated with gefitinib.
|
Lung Cancer
|
2004
|
1.27
|
|
11
|
Bright-field dual-color chromogenic in situ hybridization for diagnosing echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase-positive lung adenocarcinomas.
|
J Thorac Oncol
|
2011
|
1.23
|
|
12
|
Frequent ALK rearrangement and TTF-1/p63 co-expression in lung adenocarcinoma with signet-ring cell component.
|
Lung Cancer
|
2010
|
1.21
|
|
13
|
Overdiagnosis in lung cancer screening with low-dose computed tomography.
|
J Thorac Oncol
|
2013
|
1.14
|
|
14
|
Retrospective analysis of third-line and fourth-line chemotherapy for advanced non-small-cell lung cancer.
|
Clin Lung Cancer
|
2011
|
1.12
|
|
15
|
The usefulness of mutation-specific antibodies in detecting epidermal growth factor receptor mutations and in predicting response to tyrosine kinase inhibitor therapy in lung adenocarcinoma.
|
Lung Cancer
|
2010
|
1.10
|
|
16
|
Tumor response to chemotherapy: the validity and reproducibility of RECIST guidelines in NSCLC patients.
|
Cancer Sci
|
2003
|
1.08
|
|
17
|
c-MET/phospho-MET protein expression and MET gene copy number in non-small cell lung carcinomas.
|
J Thorac Oncol
|
2012
|
1.06
|
|
18
|
Clinical responses of large cell neuroendocrine carcinoma of the lung to cisplatin-based chemotherapy.
|
Lung Cancer
|
2005
|
1.06
|
|
19
|
Increased expression and no mutation of the Flap endonuclease (FEN1) gene in human lung cancer.
|
Oncogene
|
2003
|
1.03
|
|
20
|
Figitumumab combined with carboplatin and paclitaxel in treatment-naïve Japanese patients with advanced non-small cell lung cancer.
|
Invest New Drugs
|
2011
|
1.02
|
|
21
|
Comparison of pharmacokinetics and pharmacodynamics of docetaxel and Cisplatin in elderly and non-elderly patients: why is toxicity increased in elderly patients?
|
J Clin Oncol
|
2004
|
1.02
|
|
22
|
Association of DNA repair gene polymorphisms with response to platinum-based doublet chemotherapy in patients with non-small-cell lung cancer.
|
J Clin Oncol
|
2010
|
1.00
|
|
23
|
Combination chemotherapy with irinotecan and cisplatin for large-cell neuroendocrine carcinoma of the lung: a multicenter phase II study.
|
J Thorac Oncol
|
2013
|
0.96
|
|
24
|
Phase I study of TLR9 agonist PF-3512676 in combination with carboplatin and paclitaxel in patients with advanced non-small-cell lung cancer.
|
Cancer Sci
|
2009
|
0.96
|
|
25
|
Short hydration in chemotherapy containing cisplatin (≥75 mg/m2) for patients with lung cancer: a prospective study.
|
Jpn J Clin Oncol
|
2013
|
0.95
|
|
26
|
Circulating endothelial cells in non-small cell lung cancer patients treated with carboplatin and paclitaxel.
|
J Thorac Oncol
|
2009
|
0.93
|
|
27
|
Long-term results of concurrent chemoradiotherapy using cisplatin and vinorelbine for stage III non-small-cell lung cancer.
|
Cancer Sci
|
2012
|
0.92
|
|
28
|
Safety of BLP25 liposome vaccine (L-BLP25) in Japanese patients with unresectable stage III NSCLC after primary chemoradiotherapy: preliminary results from a Phase I/II study.
|
Jpn J Clin Oncol
|
2011
|
0.90
|
|
29
|
Risk factors for treatment-related death associated with chemotherapy and thoracic radiotherapy for lung cancer.
|
J Thorac Oncol
|
2012
|
0.89
|
|
30
|
Effect of platinum combined with irinotecan or paclitaxel against large cell neuroendocrine carcinoma of the lung.
|
Jpn J Clin Oncol
|
2007
|
0.88
|
|
31
|
Phase I study of ipilimumab in phased combination with paclitaxel and carboplatin in Japanese patients with non-small-cell lung cancer.
|
Invest New Drugs
|
2015
|
0.88
|
|
32
|
Antiproliferative action of metformin in human lung cancer cell lines.
|
Oncol Rep
|
2012
|
0.87
|
|
33
|
Retrospective analysis of safety and efficacy of low-dose docetaxel 60 mg/m2 in advanced non-small cell lung cancer patients previously treated with platinum-based chemotherapy.
|
Am J Clin Oncol
|
2003
|
0.86
|
|
34
|
A pharmacokinetic and dose escalation study of pegfilgrastim (KRN125) in lung cancer patients with chemotherapy-induced neutropenia.
|
Jpn J Clin Oncol
|
2009
|
0.85
|
|
35
|
Combination chemotherapy with carboplatin and paclitaxel for advanced thymic cancer.
|
Jpn J Clin Oncol
|
2011
|
0.85
|
|
36
|
Amrubicin monotherapy for patients with previously treated advanced large-cell neuroendocrine carcinoma of the lung.
|
Jpn J Clin Oncol
|
2011
|
0.84
|
|
37
|
Genetic variations of orosomucoid genes associated with serum alpha-1-acid glycoprotein level and the pharmacokinetics of paclitaxel in Japanese cancer patients.
|
J Pharm Sci
|
2011
|
0.84
|
|
38
|
Small-cell lung cancer with lymphadenopathy in an 18-year-old female nonsmoker.
|
Nat Clin Pract Oncol
|
2006
|
0.84
|
|
39
|
Interaction and cross-resistance of cisplatin and pemetrexed in malignant pleural mesothelioma cell lines.
|
Oncol Rep
|
2012
|
0.84
|
|
40
|
Choroidal metastasis of non-small cell lung cancer that responded to gefitinib.
|
Case Rep Ophthalmol Med
|
2013
|
0.83
|
|
41
|
Effect of metformin on residual cells after chemotherapy in a human lung adenocarcinoma cell line.
|
Int J Oncol
|
2013
|
0.81
|
|
42
|
Relation between elective nodal failure and irradiated volume in non-small-cell lung cancer (NSCLC) treated with radiotherapy using conventional fields and doses.
|
Radiother Oncol
|
2009
|
0.81
|
|
43
|
Pharmacokinetics and pharmacodynamics of weekly epoetin beta in lung cancer patients.
|
Jpn J Clin Oncol
|
2006
|
0.81
|
|
44
|
Dose-escalation study of thoracic radiotherapy in combination with pemetrexed plus Cisplatin followed by pemetrexed consolidation therapy in Japanese patients with locally advanced nonsquamous non-small-cell lung cancer.
|
Clin Lung Cancer
|
2012
|
0.80
|
|
45
|
Gender differences in treatment outcomes among patients with non-small cell lung cancer given a combination of carboplatin and paclitaxel.
|
Oncology
|
2008
|
0.80
|
|
46
|
A dose-finding and pharmacokinetic study of nedaplatin in elderly patients with advanced non-small cell lung cancer.
|
Cancer Chemother Pharmacol
|
2009
|
0.80
|
|
47
|
Brain metastases after definitive concurrent chemoradiotherapy in patients with stage III lung adenocarcinoma: carcinoembryonic antigen as a potential predictive factor.
|
Cancer Sci
|
2012
|
0.79
|
|
48
|
Genetic variations of VDR/NR1I1 encoding vitamin D receptor in a Japanese population.
|
Drug Metab Pharmacokinet
|
2007
|
0.79
|
|
49
|
Pharmacokinetic and pharmacodynamic study on amrubicin and amrubicinol in Japanese patients with lung cancer.
|
Cancer Chemother Pharmacol
|
2011
|
0.78
|
|
50
|
Phase I/II study of 3-week cycle cisplatin-gemcitabine in advanced non-small cell lung cancer.
|
Jpn J Clin Oncol
|
2002
|
0.78
|
|
51
|
Concurrent chemoradiotherapy for limited-disease small cell lung cancer in elderly patients aged 75 years or older.
|
Jpn J Clin Oncol
|
2007
|
0.78
|
|
52
|
Gender difference in hematological toxicity among lung cancer patients receiving amrubicin monotherapy.
|
Jpn J Clin Oncol
|
2012
|
0.78
|
|
53
|
Geographic variation in the second-line treatment of non-small cell lung cancer.
|
Semin Oncol
|
2006
|
0.77
|
|
54
|
Study of paclitaxel and dose escalation of cisplatin in patients with advanced non-small cell lung cancer.
|
Jpn J Clin Oncol
|
2003
|
0.77
|
|
55
|
Acute radiation esophagitis caused by high-dose involved field radiotherapy with concurrent cisplatin and vinorelbine for stage III non-small cell lung cancer.
|
Technol Cancer Res Treat
|
2013
|
0.77
|
|
56
|
Genetic variations and haplotype structures of the glutathione S-transferase genes, GSTT1 and GSTM1, in a Japanese patient population.
|
Drug Metab Pharmacokinet
|
2009
|
0.76
|
|
57
|
Alveolar hemorrhage associated with pemetrexed administration.
|
Intern Med
|
2015
|
0.75
|
|
58
|
Interferon-β produces synergistic combinatory anti-tumor effects with cisplatin or pemetrexed on mesothelioma cells.
|
PLoS One
|
2013
|
0.75
|
|
59
|
Phase 1 clinical trials in oncology.
|
N Engl J Med
|
2005
|
0.75
|
|
60
|
Potential Activity of Amrubicin as a Salvage Therapy for Merkel Cell Carcinoma.
|
Intern Med
|
2017
|
0.75
|
|
61
|
Incidence, risk factors and treatment outcomes of extravasation of cytotoxic agents in an outpatient chemotherapy clinic.
|
Jpn J Clin Oncol
|
2013
|
0.75
|
|
62
|
[Targeted therapy for solid tumors in the elderly].
|
Nihon Rinsho
|
2015
|
0.75
|
|
63
|
Clinical characteristics and functional assessment of elderly patients with cancer.
|
Rinsho Ketsueki
|
2014
|
0.75
|
|
64
|
Dose-Escalation Study of Thoracic Radiotherapy in Combination With Pemetrexed Plus Cisplatin in Japanese Patients With Locally Advanced Nonsquamous Non-Small Cell Lung Cancer: A Post Hoc Analysis of Survival and Recurrent Sites.
|
Am J Clin Oncol
|
2016
|
0.75
|
|
65
|
Serum total bilirubin as a predictive factor for severe neutropenia in lung cancer patients treated with cisplatin and irinotecan.
|
Jpn J Clin Oncol
|
2007
|
0.75
|
|
66
|
[The cutting-edge of medicine; Ethnic and gender differences in lung cancer].
|
Nihon Naika Gakkai Zasshi
|
2011
|
0.75
|
|
67
|
Long-term follow-up of patients with unresectable locally advanced non-small cell lung cancer treated with chemoradiotherapy: a retrospective analysis of the data from the Japan Clinical Oncology Group trials (JCOG0003A).
|
Cancer Sci
|
2003
|
0.75
|
|
68
|
Differences in the quality of information on the internet about lung cancer between the United States and Japan.
|
J Thorac Oncol
|
2009
|
0.75
|